|drug2797||Repeat SARS-CoV-2 IgG antibodies at 45-65 days Wiki||1.00|
|D053120||Respiratory Aspiration NIH||0.28|
|D012120||Respiration Disorders NIH||0.23|
|D012140||Respiratory Tract Diseases NIH||0.20|
There is one clinical trial.
The purpose of this multi center, open label, randomized, study is to obtain information on the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with viral pneumonia
Description: Clinical safety will be assessed by incidence of Serious Adverse Events (SAEs)Measure: incidence of Serious Adverse Events Time: 30 days
Description: Time to fever resolutionMeasure: fever resolution Time: Baseline to 30 days
Description: Number of patients requiring admission to ICUMeasure: ICU admission Time: Baseline to 30 days
Description: Time until patient no longer requires supportive oxygenMeasure: Oxygen support Time: Baseline to 30 days
Description: b.d. Stable room air saturation of 93% and above or returning to baseline saturation, whichever is lowerMeasure: Stable room air saturation Time: Baseline to 30 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports